Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Akoya Biosciences, Inc. (AKYA) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Akoya Biosciences, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1711933.
Total stock buying since 2021: $12,989,168.
Total stock sales since 2021: $2,447,276.
Total stock option exercises since 2021: $230,494.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 0 | $0 | 30,000 | $104,977 | 22,500 | $6,816 |
| 2023 | 2,423,388 | $12,108,960 | 32,500 | $174,504 | 66,500 | $40,786 |
| 2022 | 0 | $0 | 142,375 | $1,849,695 | 340,107 | $182,892 |
| 2021 | 68,573 | $880,208 | 25,100 | $318,100 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2024-06 | 0 | $0 | 15,000 | $30,697 | 15,000 | $4,544 |
| 2024-03 | 0 | $0 | 15,000 | $74,280 | 7,500 | $2,272 |
| 2023-12 | 0 | $0 | 15,000 | $65,437 | 15,000 | $4,544 |
| 2023-11 | 0 | $0 | 7,500 | $32,902 | 7,500 | $2,272 |
| 2023-09 | 20,000 | $92,020 | 0 | $0 | 0 | $0 |
| 2023-06 | 2,403,388 | $12,016,940 | 5,000 | $28,535 | 5,000 | $1,515 |
| 2023-03 | 0 | $0 | 5,000 | $47,630 | 5,000 | $1,515 |
| 2023-02 | 0 | $0 | 0 | $0 | 34,000 | $30,940 |
| 2022-12 | 0 | $0 | 82,150 | $1,067,561 | 255,000 | $111,515 |
| 2022-11 | 0 | $0 | 25,310 | $336,458 | 0 | $0 |
| 2022-09 | 0 | $0 | 29,915 | $394,416 | 5,000 | $1,515 |
| 2022-06 | 0 | $0 | 5,000 | $51,260 | 5,000 | $1,515 |
| 2022-04 | 0 | $0 | 0 | $0 | 75,107 | $68,347 |
| 2021-12 | 0 | $0 | 25,100 | $318,100 | 0 | $0 |
| 2021-11 | 68,573 | $880,208 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-06-11 | Mckelligon Brian (President and CEO) | Sale | 7,500 | 2.08 | 15,630 |
| 2024-06-11 | Mckelligon Brian (President and CEO) | Option Ex | 7,500 | .30 | 2,272 |
| 2024-06-06 | Mckelligon Brian (President and CEO) | Sale | 7,500 | 2.01 | 15,067 |
| 2024-06-06 | Mckelligon Brian (President and CEO) | Option Ex | 7,500 | .30 | 2,272 |
| 2024-03-20 | Mckelligon Brian (President and CEO) | Sale | 7,500 | 4.97 | 37,245 |
| 2024-03-20 | Mckelligon Brian (President and CEO) | Option Ex | 7,500 | .30 | 2,272 |
| 2024-03-13 | Mckelligon Brian (President and CEO) | Sale | 7,500 | 4.94 | 37,035 |
| 2023-12-19 | Mckelligon Brian (President and CEO) | Sale | 7,500 | 4.47 | 33,562 |
| 2023-12-19 | Mckelligon Brian (President and CEO) | Option Ex | 7,500 | .30 | 2,272 |
| 2023-12-12 | Mckelligon Brian (President and CEO) | Sale | 7,500 | 4.25 | 31,875 |
| 2023-12-12 | Mckelligon Brian (President and CEO) | Option Ex | 7,500 | .30 | 2,272 |
| 2023-11-20 | Mckelligon Brian (President and CEO) | Sale | 7,500 | 4.39 | 32,902 |
| 2023-11-20 | Mckelligon Brian (President and CEO) | Option Ex | 7,500 | .30 | 2,272 |
| 2023-09-07 | Pla Frederic (Chief Operating Officer) | Buy | 20,000 | 4.60 | 92,020 |
| 2023-06-12 | Ek John Frederick (CFO) | Buy | 20,000 | 5.00 | 100,000 |
| 2023-06-12 | Winkler Matthew | Buy | 203,388 | 5.00 | 1,016,940 |
| 2023-06-12 | Mendel Scott | Buy | 20,000 | 5.00 | 100,000 |
| 2023-06-12 | Raffin Thomas A. | Buy | 2,020,000 | 5.00 | 10,100,000 |
| 2023-06-12 | Lai Goldman Myla | Buy | 20,000 | 5.00 | 100,000 |
| 2023-06-12 | Shepler Robert G | Buy | 120,000 | 5.00 | 600,000 |
| 2023-06-06 | Mckelligon Brian (President/CEO) | Sale | 5,000 | 5.71 | 28,535 |
| 2023-06-06 | Mckelligon Brian (President/CEO) | Option Ex | 5,000 | .30 | 1,515 |
| 2023-03-14 | Mckelligon Brian (President/CEO) | Sale | 5,000 | 9.53 | 47,630 |
| 2023-03-14 | Mckelligon Brian (President/CEO) | Option Ex | 5,000 | .30 | 1,515 |
| 2023-02-15 | Ramachandran Niro Ph.d (Chief Business Officer) | Option Ex | 34,000 | .91 | 30,940 |
| 2022-12-22 | Driscoll Joseph (Chief Financial Officer) | Option Ex | 250,000 | .44 | 110,000 |
| 2022-12-13 | Schnettler Thomas P | Sale | 71,050 | 13.03 | 925,781 |
| 2022-12-06 | Mckelligon Brian (President/CEO) | Sale | 5,000 | 12.08 | 60,415 |
| 2022-12-06 | Mckelligon Brian (President/CEO) | Option Ex | 5,000 | .30 | 1,515 |
| 2022-12-02 | Nolan Garry Ph.d. | Sale | 1,100 | 13.25 | 14,575 |
| 2022-12-01 | Nolan Garry Ph.d. | Sale | 5,000 | 13.36 | 66,790 |
| 2022-11-16 | Nolan Garry Ph.d. | Sale | 600 | 13.25 | 7,950 |
| 2022-11-14 | Nolan Garry Ph.d. | Sale | 600 | 13.28 | 7,966 |
| 2022-11-11 | Nolan Garry Ph.d. | Sale | 20,000 | 13.29 | 265,860 |
| 2022-11-10 | Nolan Garry Ph.d. | Sale | 3,810 | 13.31 | 50,707 |
| 2022-09-14 | Nolan Garry Ph.d. | Sale | 16,610 | 13.26 | 220,164 |
| 2022-09-07 | Mckelligon Brian (President/CEO) | Sale | 5,000 | 12.83 | 64,170 |
| 2022-09-07 | Mckelligon Brian (President/CEO) | Option Ex | 5,000 | .30 | 1,515 |
| 2022-06-15 | Mckelligon Brian (President/CEO) | Sale | 5,000 | 10.25 | 51,260 |
| 2022-06-15 | Mckelligon Brian (President/CEO) | Option Ex | 5,000 | .30 | 1,515 |
| 2022-04-13 | Ramachandran Niro Ph.d (Chief Business Officer) | Option Ex | 75,107 | .91 | 68,347 |
| 2021-12-13 | Nolan Garry Ph.d. | Sale | 100 | 13.25 | 1,325 |
| 2021-12-09 | Nolan Garry Ph.d. | Sale | 25,000 | 12.67 | 316,775 |
| 2021-11-22 | Ramachandran Niro Ph.d (Chief Business Officer) | Buy | 25,000 | 13.13 | 328,300 |
| 2021-11-19 | Ramachandran Niro Ph.d (Chief Business Officer) | Buy | 73 | 12.85 | 938 |
| 2021-11-19 | Mendel Scott | Buy | 8,500 | 13.16 | 111,860 |
| 2021-11-18 | Shepler Robert G | Buy | 35,000 | 12.55 | 439,110 |
Insider trading activities including stock purchases, stock sales, and option exercises of AKYA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Akoya Biosciences, Inc. (symbol AKYA, CIK number 1711933) see the Securities and Exchange Commission (SEC) website.